Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
Open Access
- 1 November 2017
- journal article
- practice guideline
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 32 (6), 947-958
- https://doi.org/10.3904/kjim.2017.298
Abstract
In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM.Funding Information
- Korean Diabetes Association
This publication has 57 references indexed in Scilit:
- Comparison between sitagliptin as add‐on therapy to insulin and insulin dose‐increase therapy in uncontrolled Korean type 2 diabetes: CSI studyDiabetes, Obesity and Metabolism, 2012
- Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetesDiabetes Research and Clinical Practice, 2011
- A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agentsDiabetes, Obesity and Metabolism, 2011
- An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemiaDiabetes, Obesity and Metabolism, 2011
- 2011 Clinical Practice Guidelines for Type 2 Diabetes in KoreaDiabetes & Metabolism Journal, 2011
- Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy StudyDiabetes & Metabolism Journal, 2011
- The Effect of Oral Antidiabetic Agents on A1C LevelsDiabetes Care, 2010
- Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study dataCMAJ : Canadian Medical Association Journal, 2009
- Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitusEmergencias, 2007
- Glycometabolic State at Admission: Important Risk Marker of Mortality in Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial InfarctionJournal of the American College of Cardiology, 1999